?

BIOGRAPHICAL SKETCH

?

NAME: Geng Tian

?

POSITION TITLE: Deputy Director, Department of Oncology, The First Affiliated Hospital of Shenzhen University & Shenzhen Second People's Hospital

?

EDUCATION/TRAINING

?

A. Personal statement

Geng Tian is a qualified Master’s and postdoctoral tutor, with many years of medical experience. He is primarily engaged in the comprehensive, dynamic treatment of tumors according to both the latest research and the characteristics of individual patients. He specializes in tumor immunotherapy, including cell therapy and antibody therapy, tumor screening, and early diagnosis.

?

He also serves as a standing member of the Oncology Professional Committee of the China Research Hospital Association, the Honorary Chairman of the Melanoma Professional Committee of the Guangdong Cancer Association, the Chairman of the Biotherapy Professional Committee of the Shenzhen Cancer Association, a member of the Cancer Branch of the Guangdong Doctor Association, a member of the Tumor Hyperthermia Professional Committee of the Guangdong Cancer Association, and the Chairman of the Shenzhen Cancer Prevention and Early Screening Committee of the Tumor Prevention and Treatment Association of China,

?

His research is supported by a range of funding bodies, including the National Key Research and Development Program, and he has obtained more than 7 million yuan in grants.

?

B. Positions and honors

Positions

2009-present: Chief Physician, the First Affiliated Hospital of Shenzhen University & Shenzhen Second People's Hospital, Shenzhen, China

?

C. Representative publications (selected publications in recent five years ? 5-10篇)

1.Muyun Peng#, Yuancai Xie#, Xiaohua Li, Youhui Qian, Xiaon ian Tu, Xumei Yao, Fangsheng Cheng, Feiyue Xu, Deju Kong, Bing He, Chaoyu Liu, Fengjun Cao. Haoxian Yang, Fenglei Yu*, Chuanbo Xu* and Geng Tian*?(2019) Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNA.?J Med Genet; 56(10): 647-653.?

2.Yan Xia#, Xianhao Liu#, Beibei Liu, Xiaoshi Zhang* and Geng Tian*?(2018) Enhanced antitumor activity of combined megestrol acetate and arsenic trioxide treatment in liver cancer cells.?Exp Ther Med., 15(4): 4047-4055.

3.Yan Xia#, Xiaopeng Tian#, Juntao Wang, Dongjuan Qiao, Xianhao Liu, Liang Xiao, Wenli Liang, Dongcheng Ban, Junjun Chu, Jiaming Yu, Rongfu Wang, Geng Tian* and Mingjun Wang*?(2018) Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: A case report.?Oncol Lett.?16(6): 6998-7007.

4.Zongbin Liu#, Weiliang Shu#, Rui Chen, Hongtao Feng, Zongqian Hu, Yuanxiang Wang*, Geng Tian*, Aixue Liu* and Yan Chen*. (2018)?Integrated Microfluidic Chip for Rapid Capture and Drug Screening of Cancer Cells from Peripheral Blood.?Integr Canc Biol Res.?2(1):?009.

5.Ligang Xia#, Zhoufang Li#, Bo Zhou# and Geng Tian#, Lidong Zeng, Hongyu Dai, Xiaohua Li, Chaoyu Liu, Shixin Lu, Feiyue Xu, Xiaonian Tu, Fang Deng, Yuancai Xie, Weiren Huang, Jiankui He*.?(2017)?Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals.?Sci Rep. 7(1):7526-7533.

6.Yajun Zhou#, Xing Fu#, Chuanxiang Li, Xiaoyan Li, Yidan Xiao, Jing Shi, Liang Xiao, Guodai Hong, Jing Ji, Wenli Liang and Geng Tian*.??(2017)?Megestrol acetate and oxaliplatin fail to enhance the chemosensitivity of hepatocellular carcinoma in vitro and in vivo.?Int J Clin Exp Med. 10(7):10472-10480.

?

D. Research support

Ongoing projects (RMB)

1.Key Special Project of "Synthetic Biology" of National Key Research and Development Plan: Topic 2 (grant no. 2018YFA0902702). 2018-2023, PI, ￥3060000.

?

2.Shenzhen Clinical Research Project: the Third Generation CAR-T Targeting EGFR in the Treatment of Metastatic Colorectal Cancer (grant no.SZLY2017008). 2017-2019, PI, ￥300000.

?

3.Shenzhen Clinical Research Project: Clinical Study on the Treatment of Metastatic Colorectal Cancer With Four Generation EGFR CAR-T (grant no.SZLY2018020). 2018-2023, PI, ￥300000.

?

4.Shenzhen Innovation Chain and Industrial Chain Integration Project: New Generation Tumor Individualized Cell Therapy, sub project: Clinical Research of Individualized Immunocytotherapy ?(SFG [2015] 863, SFG [2015] 971). 2015-2018, PI, ￥2790000.

?

5.Special Fund Project for the Development of Strategic Emerging Industries in Shenzhen: Research on Biotherapy and Transformation Medicine of Inoperable Liver Cancer (grant no. CXZZ20120614154434310). 2012-2015, PI, ￥1000000.

?